# Design Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/design-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.designpharmaceuticals.com
- Total disclosed funding: $3M
- Latest round: Series A (Jan 12, 2022)
- Investors on record: 1

## About

Based in Massachusetts, US, and founded in 2018 by Dirk Loeffert (CEO), Design Pharmaceuticals, Inc., doing business as, Design Pharma, is involved in small molecule drug research and development by utilizing biotechnologies to gain access to previously undiscovered molecules and speed up the drug discovery process. In January 2022, Design Pharmaceuticals, Inc. raised USD 3 million in Seed funding led by new investor Virtus Inspire Ventures.

The company is a biotech firm that discovers small molecule drug compounds. The firm uses AI-guided biomining to screen compounds for G-protein coupled receptor (GPCR) screening from molecular sources such as chemical compound libraries, peptide and antibody libraries, DNA-encoded libraries, or patient samples, and build compounds to test various chemical structures built and biosynthetically create better compound candidates.

The company intends to use the January 2022 funding to further improve its discovery platform and operations.

## Funding rounds

- Series A, Jan 12, 2022, $3M — Virtus Inspire Ventures

## Investors

- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Series A